Today, the House Energy and Commerce (E&C) Committee will mark up the FDA Reauthorization Act (FDARA) of 2017 (H.R. 2430). To ensure this critical legislation passes Congress far ahead of a September 30 deadline, manufacturers urge swift action by the committee to keep H.R. 2430 on schedule. Any delay of the FDARA risks future gains in medical discovery and harm to our global standing.
In a March letter to E&C Health Subcommittee members, the National Association of Manufacturers (NAM) expressed strong support for a timely reauthorization of the Prescription Drug User Fee Act of 2017.
The FDA’s user fee program is the ultimate public–private partnership. If approved, this agreement will help the federal government and pharmaceutical and medical device manufacturers continue to drive innovation and usher in competition to bring new and groundbreaking therapies to patients.
Manufacturers urge members of the E&C Committee to support FDARA and avoid any needless risk to public health by opposing drug importation amendments. Any amendment that eases restrictions on the importation of medicines is a distraction. The NAM opposed a similar importation effort in the Senate earlier this year in a key vote letter because it could expose consumers to counterfeit and adulterated therapies. The focus must be on the advancement of new medicines and treatments as well as unambiguous support for scientific innovation by ensuring the FDARA moves forward unimpeded.
Latest posts by Robyn Boerstling (see all)
- Colorado Drug Importation Proposal is Misleading - April 12, 2019
- Additional Health Care Mandates Only Add to the Business Challenge of Rising Health Costs - April 2, 2019
- Innovation Should Not Be A Scapegoat for Rising Health Care Costs - March 20, 2019